Pei Lu1, Keliang Chen2, Zijie Wang1, Rijin Song1, Jiexiu Zhang1, Bianjiang Liu1, Guohua Zeng3, Zengjun Wang1, Wei Zhang4, Min Gu5. 1. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. 2. Department of Urology, Ningbo First Hospital, Ningbo, 315000, China. 3. Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, China. 4. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. njmuwzj@qq.com. 5. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. lancetgu@aliyun.com.
Abstract
PURPOSE: To compare the clinical efficacy and safety between the FURL with 365 μm and 200 μm holmium laser for treating nephrolithiasis. MATERIALS AND METHODS: A prospective randomized controlled trial was performed including analysis of data from 200 patients with nephrolithiasis. A total of 180 patients were randomized into two groups according to 1:1 ratio. In the 365 μm holmium laser group, kidney stones were disintegrated into less than 2 mm fragments with a 365 µm holmium laser fiber with the settings of 30-45 W under direct visualization; in the control group, the conventional 200 μm holmium laser was used. Descriptive statistics and logistic regression analyses tested the association among operation time, stone-free rate (SFR) and incidence of complications. RESULTS:Operation time in the FURL with 365 μm laser was significantly shortened and no significance was observed in the complication rate. Stone size and location were identified as two major confounding factors for the operation time and SFR. Moreover, the FURL using 365 μm laser showed less operation time for renal stones with the diameter between 1 and 2 cm, stones located in lower calyx and multiple calculi; stones larger than 2 cm and/or located in lower pole inclined to present better SFR using the FURL with 365 μm laser. CONCLUSIONS: The FURL combined with 365 μm holmium laser is safer and highly efficacious for the management of nephrolithiasis when compared to conventional FURL procedures, especially for those located in lower pole and larger than 2 cm.
RCT Entities:
PURPOSE: To compare the clinical efficacy and safety between the FURL with 365 μm and 200 μm holmium laser for treating nephrolithiasis. MATERIALS AND METHODS: A prospective randomized controlled trial was performed including analysis of data from 200 patients with nephrolithiasis. A total of 180 patients were randomized into two groups according to 1:1 ratio. In the 365 μm holmium laser group, kidney stones were disintegrated into less than 2 mm fragments with a 365 µm holmium laser fiber with the settings of 30-45 W under direct visualization; in the control group, the conventional 200 μm holmium laser was used. Descriptive statistics and logistic regression analyses tested the association among operation time, stone-free rate (SFR) and incidence of complications. RESULTS: Operation time in the FURL with 365 μm laser was significantly shortened and no significance was observed in the complication rate. Stone size and location were identified as two major confounding factors for the operation time and SFR. Moreover, the FURL using 365 μm laser showed less operation time for renal stones with the diameter between 1 and 2 cm, stones located in lower calyx and multiple calculi; stones larger than 2 cm and/or located in lower pole inclined to present better SFR using the FURL with 365 μm laser. CONCLUSIONS: The FURL combined with 365 μm holmium laser is safer and highly efficacious for the management of nephrolithiasis when compared to conventional FURL procedures, especially for those located in lower pole and larger than 2 cm.
Authors: David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman Journal: J Clin Epidemiol Date: 2010-03-25 Impact factor: 6.437
Authors: Glenn M Preminger; Dean G Assimos; James E Lingeman; Stephen Y Nakada; Margaret S Pearle; J Stuart Wolf Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Giovanni M Bariani; Anezka C R de Celis Ferrari; Maristela Precivale; Roberto Arai; Everardo D Saad; Rachel P Riechelmann Journal: Am J Clin Oncol Date: 2015-12 Impact factor: 2.339
Authors: Christian Türk; Aleš Petřík; Kemal Sarica; Christian Seitz; Andreas Skolarikos; Michael Straub; Thomas Knoll Journal: Eur Urol Date: 2015-09-04 Impact factor: 20.096